Currently we test and support the following browsers:
(St. Jude Reference #)
|Modified Influenza Virus for Monitoring and Improving Vaccine Efficiency (SJ-04-0033)|
|Description||The inventors found that the conversion of serine at position 223 to asparagine (N223) in the HA protein of the H5N1 influenza virus increased the sensitivity of a hemagglutination inhibition (HI) assay in which this protein was used. This N223 change alters receptor specificity and/or antibody-antigen binding. The inclusion of the N223 residue in the HA proteins of diagnostic reference viruses may facilitate the evaluation of vaccine efficacy in humans.|
|Keywords||Influenza, H5N1, hemagglutination inhibition assay|
|Granted Patents or Published Applications||U.S. Publication No. 2007/0031453; International Publication No. WO07/019094; European Publication No. 1924281.|
|Related Scientific References||Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG., Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines.
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12915-20.
|Licensing Opportunities||We are currently looking for licensees in fields other than veterinary use.|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: September 2008